Skip to main content
OpenTrials

Clinical trial condition

Primary Myelofibrosis (PMF)

Explore clinical trials studying Primary Myelofibrosis (PMF). Study availability and eligibility vary by location and protocol.

15 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Primary Myelofibrosis (PMF) trial results

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Summit Medical Group Oncology Berkeley Heights, New Jersey, United States
  • The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Novartis Investigative Site Buenos Aires, Buenos Aires F.D., Argentina
  • Novartis Investigative Site Capital Federal, Argentina
View all 56 locations
View Trial Details
Recruiting

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

NCT07469891

Conditions
Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, +13 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • BRCR Global - Coral Springs Coral Springs, Florida, United States
  • START Midwest, LLC Grand Rapids, Michigan, United States
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office Philadelphia, Pennsylvania, United States
View Trial Details
Recruiting

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

NCT07340138

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Novartis Investigative Site Kamogawa, Chiba, Japan
  • Novartis Investigative Site Sapporo, Hokkaido, Japan
  • Novartis Investigative Site Kamakura, Kanagawa, Japan
  • Novartis Investigative Site Kurashiki, Okayama-ken, Japan
View Trial Details
Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

NCT03441113

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations
  • GSK Investigational Site Scottsdale, Arizona, United States
  • GSK Investigational Site Orange, California, United States
  • GSK Investigational Site Stanford, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
View all 112 locations
View Trial Details
Completed

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

NCT04676529

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations
  • Comprehensive Cancer Center (UAB CCC) Birmingham, Alabama, United States
  • Novant Health Cancer Institute Winston-Salem, North Carolina, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • Liverpool Hospital Liverpool, New South Wales, Australia
View all 23 locations
View Trial Details
Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

NCT03136185

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations
  • University of Michigan Ann Arbor, Michigan, United States
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Universitatsklinikum Essen Essen, Germany
  • Azienda Ospedaliero Universitaria Careggi Florence, Italy
View Trial Details

Related conditions